Sibutramine-associated QT interval prolongation and cardiac arrest

Annals of Pharmacotherapy

Volumn 42, Issue 10, 2008, Pages 1514-1517

  Ernest, David ^a   Gershenzon, Alexander ^a   Corallo, Carmela E ^a   Nagappan, Ramesh ^a  

^a BOX HILL HOSPITAL   (Australia)

Author keywords

Cardiac arrest; QT interval; Sibutramine; Ventricular fibrillation

Indexed keywords

ACETYLSALICYLIC ACID; METOPROLOL; SIBUTRAMINE; THYROXINE;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CASE REPORT; DEFIBRILLATOR; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; HEART ARREST; HEART VENTRICLE FIBRILLATION; HUMAN; HYPOTHYROIDISM; OBESITY; PRIORITY JOURNAL; QT PROLONGATION; RESUSCITATION; SINUS TACHYCARDIA;

APPETITE DEPRESSANTS; CYCLOBUTANES; DEFIBRILLATORS, IMPLANTABLE; DRUG MONITORING; ELECTROCARDIOGRAPHY; FEMALE; HEART ARREST; HUMANS; LONG QT SYNDROME; MIDDLE AGED; OBESITY; VENTRICULAR FIBRILLATION;

EID: 52949102976     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L129     Document Type: Article

References (15)

1. Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss. A systematic review. Arch Intern Med 2004;164:994-1003.
2. Deitel M. Sibutramine warning: hypertension and cardiac arrhythmias reported (editorial). Obes Surg 2002;12:422.
3. Harrison-Woolrych M, Clark DW, Hill GR, et al. QT interval prolongation associated with sibutramine treatment. Br J Clin Pharmacol 2006;61:464-9.
4. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drag reactions. Clin Pharmacol Ther 1981;30:239-45.
5. Advisory: Health Canada investigates safety of Meridia (sibutramine). Ottawa: Health Canada, 2002 Mar 27. www.hc-sc.gc.ca/english/protection/warnings/ 2002/2002_21e.htm (accessed 2007 Nov 13).
6. James PWT. The SCOUT study: risk-benefit profile of sibutramine in overweight high-risk cardiovascular patients. Eur Heart J Suppl 2005;7:L44-8. DOI 10.1093/eurheartj/sui086
7. Sibutramine - four years experience. Aust Adv Drug React Bull 2006;25:11. www.tga.gov.au/adr/aadrb/aadr0606.htm#a3 (accessed 2007 Nov 13).
8. Torp-Pedersen C, Caterson I, Coutinho W, et al. Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J 2007;28:2915-23. Epub 26 Jun 2007. DOI 10.1093/eurheartj/ehm217
9. Sayin T, Guldal M. Sibutramine: possible cause of a reversible cardiomyopathy. Int J Cardiol 2005;99:481-2.
10. Azarisman SM, Magdi YA, Noorfaizan S, et al. Myocardial infarction induced by appetite suppressants in Malaysia. N Engl J Med 2007;357:1873-4.
11. Product information. Reductil (sibutramine hydrochloride). MIMS Online. http://mims.hcn.net.au (accessed 2007 Nov 13).
12. University of Arizona Center for Education and Research on Therapeutics (January 20, 2005). www.torsades.org (accessed 2007 Nov 13).
13. Owecki M, Michalak A, Nikisch E, et al. [Subclinical hypothyroidism influences ventricular repolarization measured by QTc interval] Polish. Przegl Lek 2006;63:185-7.
14. Owecki M, Michalak A, Nikisch E, et al. Prolonged ventricular repolarization measured by corrected QT interval (QTc) in subclinical hyperthyroidism. J Horm Metab Res 2006;38:44-7.
15. Kweon KH, Park BH, Cho CG. The effects of L-thyroxine treatment on QT dispersion in primary hypothyroidism. J Korean Med Sci 2007;22:114-6.